ID   624-mel
AC   CVCL_8054
SY   624-MEL; 624 MEL; 624 Mel; 624 mel; 624mel; 624MEL; 624; Mel-624; Mel624; MEL624
DR   BTO; BTO_0002951
DR   EFO; EFO_0006359
DR   ArrayExpress; E-MTAB-2706
DR   BioGRID_ORCS_Cell_line; 754
DR   BioSample; SAMN03471309
DR   cancercelllines; CVCL_8054
DR   CGH-DB; 9301-4
DR   ChEMBL-Cells; CHEMBL3885941
DR   Cosmic; 876683
DR   Cosmic; 905214
DR   Cosmic; 1303044
DR   Cosmic; 1559441
DR   Cosmic; 2163793
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   ESTDAB; ESTDAB-049
DR   GEO; GSM206438
DR   GEO; GSM274692
DR   PharmacoDB; 624mel_23_2019
DR   PubChem_Cell_line; CVCL_8054
DR   Wikidata; Q54604356
RX   PubMed=8027550;
RX   PubMed=8081556;
RX   PubMed=8537970;
RX   PubMed=9759882;
RX   PubMed=10048982;
RX   PubMed=10754339;
RX   PubMed=15467732;
RX   PubMed=15592718;
RX   PubMed=19340423;
RX   PubMed=23851445;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27600516;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*02:01,03:01; B*07:02,14:01; C*07:02,08:02; DPB1*15:01,20:01; DQB1*03:01:01,02:01; DRB1*04:01,07:01 (PubMed=15592718).
CC   HLA typing: A*02:01,03:01; B*07:02,14:02; C*07:02,08:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys275Trp (c.825T>G); ClinVar=VCV000485044; Zygosity=Unspecified (PubMed=23851445; PubMed=25485619).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Proteomics; HLA class I peptidome.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): ESTDAB=ESTDAB-049; PubMed=25877200; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 10,13
ST   D16S539: 14
ST   D18S51: 16
ST   D21S11: 29
ST   D3S1358: 14,16
ST   D5S818: 12
ST   D7S820: 10,12
ST   D8S1179: 12 (PubMed=25877200)
ST   D8S1179: 12,15 (Technion Genomics Center)
ST   FGA: 23,24 (Technion Genomics Center)
ST   FGA: 24 (ESTDAB=ESTDAB-049; PubMed=25877200)
ST   Penta D: 9
ST   Penta E: 7,13
ST   TH01: 9.3
ST   TPOX: 8,10
ST   vWA: 18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 35
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R.,
RA   Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K.,
RA   Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.;
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=8081556; DOI=10.1097/00002371-199407000-00002; PMCID=PMC2561308;
RA   Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A.,
RA   O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J.,
RA   Rosenberg S.A.;
RT   "Locus-specific analysis of human leukocyte antigen class I expression
RT   in melanoma cell lines.";
RL   J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994).
//
RX   PubMed=8537970; DOI=10.1093/jnci/88.2.100; PMCID=PMC2248456;
RA   Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K.,
RA   Yannelli J.R., Rosenberg S.A.;
RT   "Loss of functional beta 2-microglobulin in metastatic melanomas from
RT   five patients receiving immunotherapy.";
RL   J. Natl. Cancer Inst. 88:100-108(1996).
//
RX   PubMed=9759882; DOI=10.4049/jimmunol.161.7.3596;
RA   Wang R.-F., Johnston S.L., Zeng G., Topalian S.L.,
RA   Schwartzentruber D.J., Rosenberg S.A.;
RT   "A breast and melanoma-shared tumor antigen: T cell responses to
RT   antigenic peptides translated from different open reading frames.";
RL   J. Immunol. 161:3596-3606(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; PMCID=PMC2072935;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382;
RA   Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y.,
RA   Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.;
RT   "A tumor-infiltrating lymphocyte from a melanoma metastasis with
RT   decreased expression of melanoma differentiation antigens recognizes
RT   MAGE-12.";
RL   J. Immunol. 164:4382-4392(2000).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27600516; DOI=10.1007/s00262-016-1897-3; PMCID=PMC5509013;
RA   Gloger A., Ritz D., Fugmann T., Neri D.;
RT   "Mass spectrometric analysis of the HLA class I peptidome of melanoma
RT   cell lines as a promising tool for the identification of putative
RT   tumor-associated HLA epitopes.";
RL   Cancer Immunol. Immunother. 65:1377-1393(2016).
//